The NPY/AgRP neuron and energy homeostasis

International Journal of Obesity

Volumn 25, Issue , 2001, Pages S56-S62

  Morton, G J ^a   Schwartz, M W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adiposity; Energy homeostasis

Indexed keywords

AGOUTI RELATED PROTEIN; INSULIN; INSULIN RECEPTOR; LEPTIN; LEPTIN RECEPTOR; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; NEUROPEPTIDE Y;

ARCUATE NUCLEUS; CONFERENCE PAPER; DIABETES MELLITUS; ENERGY BALANCE; ENERGY METABOLISM; FOOD INTAKE; HUMAN; HYPERPHAGIA; NEGATIVE FEEDBACK; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WEIGHT GAIN;

ADIPOSE TISSUE; ANIMALS; ENERGY METABOLISM; FEEDBACK; HOMEOSTASIS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEURONS; NEUROPEPTIDE Y; PROTEINS;

AGOUTI;

EID: 0035712816     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0801915     Document Type: Article

References (75)

1. Kennedy G. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc of Lond 1953; 140: 578-592.
2. Coleman D. Effects of parabiosis of obese with diabetes normal mice. Diabetologia 1973; 9: 294-298.
3. Coleman DL. Obese and diabetes: Two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978; 14: 141–148.
4. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
5. Chua SC, White, DW, Wu-Peng S, Liu S-M, Okada N, Kershaw EE, Chung WK, Power-Kehoe L, Chua M, Tartaglia LA, Leibel RL. Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr). Diabetes 1996; 45: 1141-1143.
6. Considine RV, Considine EL, Williams CJ, Nyce MR, Magosin SA, Bauer TL, Rosato EL, Colberg J, Caro JF. Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J Clin Invest 1995; 95: 2986-2988.
7. Bagdade JD, Bierman EL, Porte D Jr. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 1967; 46: 1549–1557.
8. Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte D Jr. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nature Med 1996; 2: 589-593.
9. Baskin DG, Wilcox BJ, Figlewicz DP, Dorsa DM. Insulin and insulin-like growth factors in the CNS. Trends Neurosci 1988; 11: 107-111.
10. Baskin DG, Breininger JF, Schwartz MW. Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. Diabetes 1999; 48: 828-833.
11. Campfield LA, Smith FJ, Guisez Y, Devos R Burn P. Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546–549.
12. Weigle DS, Bukowski TR, Foster DC, Holderman S, Kramer JM, Lasser G, Lofton-Day CE, Prunkard DE, Raymond C, Kuijper JL. Recombinant ob protein reduces feeding and body weight in the ob=ob mouse. J Clin Invest 1995; 96: 2065-2070.
13. Woods SC, Lotter EC, McKay LD, Porte D. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 1979; 282: 503-505.
14. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122-2125.
15. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 391: 900-904.
16. Tatemoto K, Rokaeus A, Jornvall H, McDonald TJ, Mutt V. Galanin—a novel biologically active peptide from porcine intestine. FEBS Lett 1983; 164: 124-128.
17. Chronwall BM, DiMaggio DA, Massari VJ, Pickel VM, Ruggiero DA, O’Donohue TL. The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience 1985; 15: 1159-1181.
18. Morris BJ. Neuronal localisation of neuropeptide Y gene expression in rat brain. J Comp Neurol 1989; 290: 358-368.
19. Clark JT, Kalra PS, Crowley WR, Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 1984; 115: 427-429.
20. Miner JL, Della-Fera MA, Paterson JA, Baile CA. Lateral cerebroventricular injection of neuropeptide Y stimulates feeding in sheep. Am J Physiol 1989; 257: R383-387.
21. Larsen PJ, Tang-Christensen M, Stidsen CE, Madsen K, Smith MS, Cameron JL. Activation of central neuropeptide Y Y1 receptors potently stimulates food intake in male rhesus monkeys. J Clin Endocrinol Metab 1999; 84: 3781-3791.
22. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF. Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986; 7: 1189-1192.
23. Egawa M, Yoshimatsu H, Bray GA. Effect of corticotropin releasing hormone and neuropeptide Y on electrophysiological activity of sympathetic nerves to interscapular brown adipose tissue. Neuroscience 1990; 34: 771-775.
24. Billington CJ, Briggs JE, Grace M, Levine AS Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism. Am J Physiol 1991; 260: R321-R327.
25. Zarjevski N, Cusin I, Vettor R, Rohner Jeanrenaud F, Jeanrenaud B. Intracerebroventricular administration of neuropeptide Y to normal rats has divergent effects on glucose utilization by adipose tissue and skeletal muscle. Diabetes 1994; 43: 764-769.
26. Vettor R, Zarjevski N, Cusin I, Rohner Jeanrenaud F, Jeanrenaud B. Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats. Diabetologia 1994; 37: 1202-1208.
27. Sainsbury A, Rohner Jeanrenaud F, Grouzmann E, Jeanrenaud B. Acute intracerebroventricular administration of neuropeptide Y stimulates corticosterone output and feeding but not insulin output in normal rats. Neuroendocrinology 1996; 63: 318-326.
28. Ong JM, Kirchgessner TG, Schotz MC, Kern PA. Insulin increases the synthetic rate and messenger RNA level of lipoprotein lipase in isolated rat adipocytes. J Biol Chem 1988; 263: 12933-12938.
29. Terrettaz J, Cusin I, Etienne J, Jeanrenaud B. In vivo regulation of adipose tissue lipoprotein lipase in normal rats made hyperinsulinemic and in hyperinsulinemic genetically-obese (fa=fa) rats. Int J Obes Relat Metab Disord 1994; 18: 9-15
30. McMinn JE, Seeley RJ, Wilkinson CW, Havel PJ, Woods SC, Schwartz MW. NPY-induced overfeeding suppresses hypothalamic NPY mRNA expression: potential roles of plasma insulin and leptin. Regul Pept 1998; 75-76: 425-431.
31. Hulsey MG, Pless CM, White BD Martin RJ. ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release. Regul Pept 1995; 59: 207-214.
32. Shibasaki T, Oda T, Imaki T, Ling N, Demura H. Injection of antineuropeptide Y gamma-globulin into the hypothalamic paraventricular nucleus decreases food intake in rats. Brain Res 1993; 601: 313-316.
33. Kanatani A, Ito J, Ishihara A, Iwaasa H, Fukuroda T, Fukami T, MacNeil DJ, Van der Ploeg LH, Ihara M. NPY-induced feeding involves the action of a Y1-like receptor in rodents. Regul Pept 1998; 75-76: 409-415.
34. Kanatani A, Kanno T, Ishihara A, Hata M, Sakuraba A, Tanaka T, Tsuchiya Y, Mase T, Fukuroda T, Fukami T, Ihara M. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem Biophys Res Commun 1999; 266: 88-91.
35. Morgan DG, Small CJ, Abusnana S, Turton M, Gunn I, Heath M, Rossi M, Goldstone AP, O’Shea D, Meeran K, Ghatei M, Smith DM, Bloom S. The NPY Y1 receptor antagonist BIBP 3226 blocks NPY induced feeding via a non-specific mechanism. Regul Pept 1998; 75-76: 377-382.
36. Pedrazzini T, Seydoux J, Kunstner P, Aubert JF, Grouzmann E, Beermann F, Brunner HR. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nature Med 1998; 4: 722-726.
37. Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, Nakamura M. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc Natl Acad Sci USA 1998; 95: 15659-15664.
38. Kanatani A, Ishihara A, Iwaasa H, Nakamura K, Okamoto O, Hidaka M, Ito J, Fukuroda T, MacNeil DJ, Van der Ploeg LH, Ishii Y, Okabe T, Fukami T, Ihara M. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem Biophys Res Commun 2000; 272: 169-173.
39. Parker EM, Balasubramaniam A, Guzzi M, Mullins DE, Salisbury BG, Sheriff S, Witten MB, Hwa JJ. [D-Trp(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intake. Peptides 2000; 21: 393-399.
40. Cabrele C, Langer M, Bader R, Wieland HA, Doods HN, Zerbe O, Beck-Sickinger AG. The first selective agonist at the neuropeptide Y Y5-receptor increases food Intake in rats. J Biol Chem 2000; 275: 36043-36048.
41. Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nature Med 1998; 4: 718-721.
42. Sahu A, Kalra PS, Kalra SP Food deprivation and ingestion induce reciprocal changes in neuropeptide Y concentrations in the paraventricular nucleus. Peptides 1988; 9: 83-86.
43. Williams G, Gill JS, Lee YC, Cardoso HM, Okpere BE, Bloom SR. Increased neuropeptide Y concentrations in specific hypothalamic regions of streptozocin-induced diabetic rats. Diabetes 1989; 38: 321-327.
44. Pickavance L, Dryden S, Hopkins D, Bing C, Frankish H, Wang Q, Vernon RG, Williams G. Relationships between hypothalamic neuropeptide Y and food intake in the lactating rat. Peptides 1996; 17: 577-582.
45. Wilding JP, Gilbey SG, Bailey CJ, Batt RA, Williams G, Ghatei MA, Bloom SR. Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob=ob) mouse. Endocrinology 1993; 132: 1939-1944.
46. Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G, Prunkard DE, Porte DJ, Woods SC, Seeley RJ, Weigle DS. Specificity of leptin action on elevated blood glucose levels and hypothalmic neuropeptide Y gene expression in ob=ob mice. Diabetes 1996; 45: 531-535.
47. Chua SC Jr, Brown AW, Kim J, Hennessey KL, Leibel RL, Hirsch J. Food deprivation and hypothalamic neuropeptide gene expression: effects of strain background and the diabetes mutation. Brain Res Mol Brain Res 1991; 11: 291-299.
48. Beck B, Burlet A, Nicolas JP, Burlet C. Hypothalamic neuropeptide Y (NPY) in obese Zucker rats: implications in feeding and sexual behaviors. Physiol Behav 1990; 47: 449-453.
49. Mercer JG, Moar KM, Rayner DV, Trayhurn P, Hoggard N. Regulation of leptin receptor and NPY gene expression in hypothalamus of leptin-treated obese (ob=ob) and cold-exposed lean mice. FEBS Lett 1997; 402: 185-188.
50. Erickson JC, Hollopeter G, Palmiter RD. Attenuation of the obesity syndrome of ob=ob mice by the loss of neuropeptide Y. Science 1996; 274: 1704-1707.
51. Mercer JG, Hoggard N, Williams LM, Lawrence CB, Hannah LT, Morgan PJ, Trayhurn P. Coexpression of leptin receptor and preproneuropeptide Y mRNA in arcuate nucleus of mouse hypothalamus. Neuroendocrinol 1996; 8: 733-735.
52. Schwartz MW, Sipols AJ, Marks JL, Sanacora G, White JD, Scheurink A, Kahn SE, Baskin DG, Woods SC, Figlewicz DP, Porte DJ. Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology 1992; 130: 3608-3616.
53. Sipols AJ, Baskin DG, Schwartz MW. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 1995; 44: 147-151.
54. Erickson J, Clegg K, Palmiter R. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996; 381: 415-418.
55. Sindelar DK, Mystkowski P, Marsh DJ, Palmiter RD, Schwartz MW. Attenuation of diabetic hyperphagia in neuropeptide-Y deficient mice. Diabetes 1999; 48: A26, O112.
56. Shutter JR, Graham M, Kinsey AC, Scully S, Luthy R, Stark KL. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev 1997; 11: 593-602.
57. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997; 278: 135-138.
58. Bultman SJ, Michaud EJ, Woychik RP. Molecular characterization of the mouse agouti locus. Cell 1992; 71: 1195-1204.
59. Miller MW, Duhl DM, Vrieling H, Cordes SP, Ollmann MM, Winkes BM, Barsh GS. Cloning of the mouse agouti gene predicts a secreted protein ubiquitously expressed in mice carrying the lethal yellow mutation. Genes Dev 1993; 7: 454-467.
60. Schwartz MW, Seeley RJ, Woods SC, Weigle DS, Campfield LA, Burn P, Baskin DG. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 1997; 46: 2119-2123.
61. Mizuno TM, Kleopoulos SP, Bergen HT, Roberts JL, Priest CA Mobbs CV. Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting in ob=ob and db=db mice, but is stimulated by leptin. Diabetes 1998; 47: 294-297.
62. Thornton JE, Cheung CC, Clifton DK, Steiner RA. Regulation of hypothalamic proopiomelanocortin mRNA by leptin in ob=ob mice. Endocrinology 1997; 138: 5063-5066.
63. Cheung CC, Clifton DK, Steiner, RA. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 1997; 138: 4489-4492.
64. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, DelValle J, Yamada T. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 1993; 268: 15174-15179.
65. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994; 8: 1298-1308.
66. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997; 385: 165-168.
67. Giraudo SQ, Billington CJ, Levine AS. Feeding effects of hypothalamic injection of melanocortin-4 receptor ligands. Brain Research 1998; 809: 302-306.
68. Huszar D, Lynch C, Fairchild-Huntress V, Dunmore J, Fang Q, Berkemeier L, Gu W, Kesterson R, Boston B, Cone R, Smith F, Campfield L, Burn P, Lee F. Targeted distruption of the melanocortin- 4 receptor results in obesity in mice. Cell 1997; 88: 131-141.
69. Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of AgRP and NPY in fasting-activated hypothalamic neurons. Nature Neurosci 1998; 1: 271-272.
70. Broberger C, Johansen J, Johansson C, Schalling M, Hokfelt T. The neuropeptide Y=agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci USA 1998; 95: 15043-15048.
71. Ebihara K, Ogawa Y, Katsuura G, Numata Y, Masuzaki H, Satoh N, Tamaki M, Yoshioka T, Hayase M, Matsuoka N, Aizawa-Abe M, Yoshimasa Y, Nakao K. Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes 1999; 48: 2028-2033.
72. Havel PJ, Hahn TM, Sindelar DK, Baskin DG, Dallman MF, Weigle DS, Schwartz MW. Effects of streptozotocin-induced diabetes and insulin treatment on the hypothalamic melanocortin system and muscle uncoupling protein 3 expression in rats. Diabetes 2000; 49: 244-252.
73. Rossi M, Kim MS, Morgan DG, Small CJ, Edwards CM, Sunter D, Abusnana S, Goldstone AP, Russell SH, Stanley SA, Smith DM, Yagaloff K, Ghatei MA, Bloom SR. A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology 1998; 139: 4428-4431.
74. Hagan MM, Rushing PA, Pritchard LM, Schwartz MW, Strack AM, Van Der Ploeg LH, Woods SC, Seeley RJ. Long-term orexigenic effects of AgRP-(83-132) involve mechanisms other than melanocortin receptor blockade. Am J Physiol Regul Integr Comp Physiol 2000; 279: R47-R52.
75. Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-671.